Where to Buy CJC Peptide: Pure Grade Labs Research Grade
CJC-1295 DAC
GHRH Analogue Research
Last Updated: May 2026
If you are searching to buy CJC peptide in the UK, the first thing you need to understand is that not all CJC peptides are the same — and buying the wrong form will compromise your research before you even begin. The term “CJC” gets used interchangeably in research literature and supplier listings to refer to two distinct compounds with meaningfully different pharmacokinetic profiles: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC, also called Mod GRF 1-29. Knowing which form you need — and sourcing it from a supplier who can verify exactly what they have supplied — is the foundation of reliable GHRH analogue research. Pure Grade Labs supplies CJC-1295+DAC 10mg verified to ≥99% purity by HPLC with a batch-specific Certificate of Analysis, from UK-based stock. This guide explains the CJC distinction, what to look for in a supplier, the UK legal position, and the research applications that make CJC-1295+DAC the form most commonly sought by researchers investigating sustained GHRH receptor stimulation and GH secretion kinetics.
Key Takeaways
- CJC-1295+DAC and Mod GRF 1-29 are not the same compound: Both are modified GHRH analogues, but the Drug Affinity Complex modification in CJC-1295+DAC dramatically extends half-life — from minutes to approximately 19 days — making them appropriate for entirely different research protocols. When searching to buy CJC, confirming which form a supplier actually stocks is essential.
- CJC-1295+DAC produced sustained GH elevation lasting 1–2 weeks after a single dose: In the landmark Alba et al. (2006) clinical study in 21 healthy adults, a single administration of CJC-1295 with DAC produced measurable GH elevation persisting for 1–2 weeks — demonstrating the pharmacodynamic consequence of the extended half-life conferred by the DAC modification.
- Purity matters enormously for reliable research: Low-quality CJC from unverified suppliers can be 60–70% pure at best — meaning a significant fraction of what is weighed and used in an experiment is not CJC-1295 at all. This renders dose-response data unreliable and cross-study comparisons meaningless.
- CJC-1295 is not a controlled substance in the UK: Unlike some research peptides that exist in regulatory grey areas, CJC-1295+DAC has no controlled substance classification under the Misuse of Drugs Act 1971 and is legal to purchase as a research chemical in the UK.
- Pure Grade Labs stocks CJC-1295+DAC specifically: CJC-1295+DAC 10mg is supplied as lyophilised powder with HPLC ≥99% purity verification and a batch-specific COA — not a generic template document. UK stock, shipped from within the UK.
Buy CJC-1295+DAC — UK Research Supply
CJC-1295+DAC 10mg. HPLC ≥99% purity. Batch-specific COA. Lyophilised powder. UK stock — not for human consumption.
The CJC Confusion: Why Searching “Buy CJC” Is Not Straightforward
The term “CJC” originates from the Canadian research company ConjuChem Technologies, which developed a family of modified GHRH (growth hormone-releasing hormone) analogues in the early 2000s. The original research programme produced several CJC-numbered compounds, of which two have remained in active use in peptide research: CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF 1-29) and CJC-1295 with DAC. Both are structural analogues of the first 29 amino acids of native GHRH — which is itself a 44-amino acid hypothalamic peptide that stimulates GHRH receptor signalling at pituitary somatotrophs to drive GH release. However, the pharmacokinetic profiles of the two forms diverge dramatically as a direct consequence of the Drug Affinity Complex (DAC) modification — and this divergence makes them appropriate for entirely different research designs.
When researchers or suppliers simply refer to “CJC peptide” or “buy CJC” without specifying whether DAC is present, the distinction is being obscured — either through imprecision or through deliberate ambiguity. For any researcher designing a study around GH secretion kinetics, GHRH receptor binding duration, or pulsatile versus sustained GH release modelling, this is not a minor labelling issue. It is the difference between two functionally distinct research tools.
CJC-1295 Without DAC (Mod GRF 1-29)
Mod GRF 1-29 (CJC-1295 without DAC) is a 29-amino acid GHRH analogue incorporating four amino acid substitutions relative to native GHRH(1-29) to improve metabolic stability and GHRH receptor binding affinity. Its half-life in biological systems remains relatively short — in the range of 15 to 60 minutes — because it lacks the albumin-binding modification present in the DAC version. This shorter duration of action makes it more appropriate for research designs that aim to mimic the pulsatile pattern of natural GHRH secretion: repeated, relatively short-acting stimulation of the GHRH receptor to model endogenous GH pulse architecture.
Mod GRF 1-29 is sometimes researched in combination with GHRP compounds such as GHRP-2 or ipamorelin in research combinations designed to investigate synergistic GH secretagogue effects. Because it acts over a shorter time window, it is paired with GHRPs in research designs that use multiple administrations per research session.
CJC-1295 With DAC: The Extended-Release GHRH Analogue
CJC-1295+DAC incorporates the same modified 29-amino acid GHRH core but adds a maleimidopropionate Drug Affinity Complex that enables covalent binding to serum albumin after administration. Albumin is the most abundant protein in blood plasma and has a half-life of approximately 19–21 days. By binding covalently to circulating albumin, CJC-1295+DAC effectively piggybacks on albumin’s extended circulation time — converting what would be a short-acting GHRH analogue into a long-acting GHRH depot system.
The pharmacokinetic data published by Jette et al. (2005) in Endocrinology demonstrated a half-life of approximately 19 days for CJC-1295+DAC in rodent and primate models, compared with approximately 7 minutes for native GHRH. This roughly 4,000-fold extension in half-life is the distinguishing feature of the DAC-modified form. CAS number for CJC-1295+DAC is 863288-34-0, and molecular weight is approximately 3,800 Da — both useful data points for confirming a supplier is selling the correct compound rather than a cheaper analogue or truncated fragment.
When researchers search to buy CJC-1295 or buy CJC1295 for research into sustained GHRH receptor stimulation, extended GH elevation studies, or reduced administration frequency designs, CJC-1295+DAC is the compound they are looking for. Pure Grade Labs stocks CJC-1295+DAC 10mg specifically — not the Mod GRF 1-29 form — and the product is clearly labelled with full CAS number, molecular weight, and batch-specific COA documentation.
What to Look for When You Buy CJC Peptide: Supplier Standards
The quality of CJC-1295 available from different suppliers varies enormously — and in ways that are not visible from a product listing. This matters because research data derived from a low-purity peptide is not reproducible or comparable with literature-cited findings. The research value of any CJC experiment is only as strong as the purity of the compound used. Here are the standards worth applying when selecting a supplier.
HPLC Purity Verification — ≥99% Is the Research Standard
High Performance Liquid Chromatography (HPLC) is the gold-standard analytical method for peptide purity assessment. It separates a peptide sample by component and quantifies each component’s relative abundance — giving a precise purity percentage for the target compound. A CJC-1295+DAC sample tested to ≥99% purity by HPLC means that less than 1% of the material in the vial is anything other than CJC-1295+DAC: no synthesis by-products, no truncated fragments, no contaminating analogues.
Suppliers that do not provide HPLC data — or that provide only Mass Spectrometry (MS) data — are not providing full purity verification. MS confirms the molecular identity of a compound but does not quantify purity. A sample that is 65% CJC-1295+DAC and 35% synthesis impurities will pass an MS identity test and appear to be the correct molecule. Only HPLC reveals the actual purity fraction.
Low-quality CJC from unverified or low-cost overseas manufacturers commonly comes in at 60–70% purity. In practical research terms, this means that if you calculate a 1mg dose based on vial weight, the actual amount of active CJC-1295+DAC you are administering to a model system is somewhere between 0.6mg and 0.7mg — and that discrepancy compounds across the entire experiment.
Batch-Specific COA — Not a Template Document
A Certificate of Analysis (COA) is only meaningful if it is genuinely batch-specific — meaning it was generated from analytical testing of the exact batch of material being supplied to you. A generic COA template, or a COA that contains no batch number, no testing date, and no analyst reference, provides no meaningful assurance about the material in your vial. It is essentially a marketing document rather than an analytical record.
When evaluating a CJC supplier, look for a COA that specifies: batch number, HPLC purity percentage (not just a pass/fail), testing date, molecular weight confirmation, and ideally the testing laboratory. Pure Grade Labs provides batch-specific COA documentation with every order of CJC-1295+DAC 10mg — the COA is tied to the batch number of the vials shipped, not to a generic product template.
Lyophilised Powder Form for Research Stability
CJC-1295+DAC should be supplied as lyophilised (freeze-dried) powder. Lyophilisation removes water from the peptide under vacuum, converting it to a stable solid state that is far more resistant to degradation during storage and transit than a pre-reconstituted liquid solution. Peptides in solution are vulnerable to hydrolysis, oxidation, and bacterial contamination — degradation pathways that are largely arrested in lyophilised form.
Suppliers offering CJC in pre-mixed liquid form are either offering a less stable product or are not manufacturing to research-grade standards. For reproducible laboratory research, lyophilised powder — reconstituted fresh with bacteriostatic water at the point of use — is the correct preparation format.
UK-Based Supply and Cold Chain Integrity
Peptides are temperature-sensitive biomolecules. Long transit times — particularly from manufacturers in China or the United States with multi-week international shipping — expose lyophilised peptides to elevated temperatures, humidity variation, and customs delays that degrade product quality. UK-based supply means shorter transit windows, less temperature exposure during shipping, no import customs delays, and faster delivery times.
When sourcing CJC peptide UK for your research programme, verifying that the supplier holds UK stock — not that they simply have a UK-facing website shipping from overseas — is worth doing. Pure Grade Labs holds stock domestically and ships within the UK without the transit risks associated with international supply chains.
Is It Legal to Buy CJC-1295 in the UK?
Yes. CJC-1295+DAC is not a controlled substance under the Misuse of Drugs Act 1971, is not classified as a Prescription Only Medicine (POM) under the Human Medicines Regulations 2012, and is not scheduled under the Psychoactive Substances Act 2016. It is legal to purchase, possess, and use for legitimate research purposes in the UK as a research chemical.
This clear legal position distinguishes CJC-1295+DAC from compounds like GLP-1 receptor agonists (semaglutide, tirzepatide) which do have POM status in the UK and require a more carefully considered compliance framework for research supply. CJC-1295+DAC sits in the same legal category as the majority of research peptides — clearly permissible for purchase and research use in the UK, provided the compound is sourced and used for legitimate scientific research purposes and not for human consumption.
All products supplied by Pure Grade Labs — including CJC-1295+DAC 10mg — are sold strictly as research chemicals for laboratory use only, not for human consumption, self-administration, or therapeutic purposes.
CJC-1295+DAC vs Mod GRF 1-29: Comparison for Researchers
| Parameter | CJC-1295+DAC | Mod GRF 1-29 (CJC no DAC) |
|---|---|---|
| CAS Number | 863288-34-0 | 863288-34-0 (same core) |
| Molecular Weight | ~3,800 Da | ~3,367 Da |
| Half-life | ~19 days (albumin-bound) | 15–60 minutes |
| DAC Modification | Yes — maleimidopropionate DAC enables albumin binding | No |
| GH Elevation Duration | 1–2 weeks after single dose (Alba et al. 2006) | Hours (requires frequent dosing) |
| Research Application | Sustained GHRH receptor stimulation, extended GH kinetics studies, low-frequency dosing protocols | Pulsatile GH release modelling, multiple-dose designs, research combinations with GHRPs |
| UK Legal Status | Legal research chemical — not a POM or controlled substance | Legal research chemical — not a POM or controlled substance |
Research Applications: What CJC-1295+DAC Is Studied For
GHRH Receptor Stimulation and GH Secretion Kinetics
The primary research interest in CJC-1295+DAC derives from its ability to stimulate GHRH receptors on pituitary somatotrophs over an extended time course. Native GHRH is cleared from circulation within minutes, making sustained receptor stimulation impossible without frequent administration. CJC-1295+DAC resolves this experimental limitation by maintaining circulating GHRH agonist activity for days to weeks after a single administration, enabling researchers to study the downstream consequences of prolonged GHRH receptor activation on GH secretion patterns, IGF-1 responses, and pituitary somatotroph physiology.
The Alba et al. (2006) study published in the Journal of Clinical Endocrinology and Metabolism remains the most cited clinical data for CJC-1295+DAC. In 21 healthy adult subjects, a single subcutaneous administration produced GH elevation that persisted for 1–2 weeks, with dose-dependent increases in both peak GH and IGF-1 levels. Mean GH levels increased 2–10 fold compared to baseline across dose groups, and mean IGF-1 levels increased by 1.5–3 fold. This trial established the proof-of-concept for weekly or biweekly dosing frequency in GH kinetics research designs — a meaningful departure from the multiple-daily-dose schedules required for Mod GRF 1-29.
GH Secretagogue Research Combinations: CJC + GHRP
One of the most well-documented areas of GH secretagogue research involves the combination of a GHRH analogue with a GHRP (growth hormone-releasing peptide). The rationale is mechanistic: GHRH analogues act on the GHRH receptor to increase the amplitude of GH pulses, while GHRPs act on the ghrelin receptor (GHSR-1a) through a distinct signalling pathway to amplify GH release. Research literature indicates these two mechanisms are synergistic rather than simply additive — simultaneous activation of both pathways produces greater GH release than either compound alone at comparable concentrations.
For researchers investigating this synergistic GH release model, GHRP-2 is one of the most studied GHRPs in combination research designs. GHRP-2 is a potent, synthetic hexapeptide GHRH secretagogue that acts at the ghrelin receptor, and is available from Pure Grade Labs for laboratory research. The GH Optimization Research Stack combines CJC-1295+DAC and GHRP-2 as a research combination for investigators studying dual-pathway GH secretagogue effects. Ipamorelin represents an alternative GHRP in this research context, valued for its high selectivity for GH release relative to other GHRPs and its more limited effect on cortisol and prolactin secretion in published animal model research.
Somatotroph Physiology and Long-Duration GHRH Agonism
CJC-1295+DAC is also used in basic research into pituitary somatotroph function. Because it maintains GHRH receptor occupancy over extended periods, it is a useful tool for studying receptor desensitisation and resensitisation dynamics, the relationship between chronic GHRH stimulation and somatotroph proliferation, and the feedback mechanisms governing GH axis homeostasis. Research designs that previously required continuous infusion of GHRH to model chronic exposure can, in appropriate models, use CJC-1295+DAC to achieve sustained receptor stimulation without the experimental complexity of osmotic pump implants or repeated injections.
CJC-1295+DAC + GHRP-2 Research Combination
For researchers studying dual-pathway GH secretagogue mechanisms. Both compounds available individually or as the GH Optimization Research Stack. HPLC ≥99%. UK stock.
What the Published Research Shows: CJC-1295+DAC Clinical Data
The clinical evidence base for CJC-1295+DAC is anchored in the work from Alba et al. (2006) and the pharmacokinetic studies from Jette et al. (2005) — both of which established the fundamental PK/PD profile that makes this compound useful as a research tool.
The Jette et al. (2005) study in Endocrinology characterised the albumin-binding mechanism underpinning DAC’s extended half-life. The study demonstrated that the maleimidopropionate group on the DAC modification undergoes a thiol-exchange reaction with a cysteine-34 residue on serum albumin following administration. This covalent bond formation is the pharmacological basis for the compound’s extended circulation. The resulting half-life of approximately 19 days in animal models reflects albumin’s own circulatory half-life — the DAC modification effectively converts CJC-1295 into an albumin-tethered GHRH agonist.
The Alba et al. (2006) Phase I/II human study administered single doses of CJC-1295+DAC ranging from 30 mcg/kg to 120 mcg/kg subcutaneously to 21 healthy adults (and additional multiple-dose cohorts). Key findings included: dose-dependent increases in mean GH AUC (area under the curve) over the study period; sustained mean GH elevation for 1–2 weeks post-administration; dose-dependent increases in IGF-1 levels (1.5–3x above baseline); and a safety profile in which the compound was well tolerated at all doses tested, with no serious adverse events reported. The GH increase was characterised not as a blunted single peak but as an extended elevation preserving pulsatile GH release architecture — an important distinction for researchers interested in physiological GH modelling rather than supraphysiological GH spikes.
These published findings establish CJC-1295+DAC’s value as a research tool for extended GHRH agonism studies — distinct from what is achievable with native GHRH or the short-acting Mod GRF 1-29 form.
Pure Grade Labs: How We Supply CJC-1295+DAC for UK Research
Pure Grade Labs supplies CJC-1295+DAC 10mg as lyophilised powder, HPLC-verified to ≥99% purity, with a batch-specific Certificate of Analysis. The COA is tied to the batch number of the material supplied — it is not a generic product template, and it is accessible via QR code on the product label for direct verification. Every vial states CAS 863288-34-0 and molecular weight clearly on the label.
We stock domestically in the UK, which means shorter transit times, no international customs exposure, and consistent cold-chain management from storage through to delivery. Our products are not imported on a per-order basis from overseas manufacturers — we hold inventory, which enables faster dispatch and consistent batch traceability.
All Pure Grade Labs products are sold strictly as research chemicals for laboratory use only. CJC-1295+DAC is supplied for in vitro research, cell-based assays, and preclinical investigation. Not for human consumption. Not for self-administration. Researchers requiring bacteriostatic water for reconstitution can source this from Pure Grade Labs as part of their research supply order.
“A research team sourcing CJC for a GH kinetics study received a vial from an overseas supplier, ran their HPLC before use, and found purity at 68%. Their entire study design had assumed 99%+ — their dose calculations, their dose-response curve, their control group baseline assumptions. They had to discard the batch and reorder. The time cost was six weeks. The financial cost was the experiment itself. The data cost was the comparison with a published study their protocol was designed to replicate. This is why purity verification is not a nice-to-have. It is the minimum viable condition for research that means anything.”
Frequently Asked Questions: Buying CJC Peptide
What is the difference between CJC-1295 with DAC and CJC-1295 without DAC?
CJC-1295+DAC contains a Drug Affinity Complex modification that enables covalent binding to serum albumin, extending its half-life to approximately 19 days. CJC-1295 without DAC (Mod GRF 1-29) lacks this modification and has a half-life of 15–60 minutes. They are appropriate for different research designs: CJC-1295+DAC for sustained extended GHRH receptor stimulation studies; Mod GRF 1-29 for pulsatile GH release modelling with frequent dosing. Both are GHRH analogues but are not interchangeable as research tools.
Is it legal to buy CJC-1295 in the UK?
Yes. CJC-1295+DAC is not a controlled substance under the Misuse of Drugs Act 1971, is not classified as a Prescription Only Medicine, and is not scheduled under the Psychoactive Substances Act 2016. It is legal to purchase and possess for legitimate laboratory research in the UK. Pure Grade Labs supplies CJC-1295+DAC strictly as a research chemical — not for human consumption.
Why does purity matter so much for CJC research?
Purity determines the actual amount of active compound in a weighed sample. At 70% purity, a nominal 1mg dose contains only 0.7mg of CJC-1295+DAC, with the remaining 0.3mg consisting of synthesis impurities, truncated peptide fragments, or uncharacterised by-products. This discrepancy makes dose-response data unreliable, prevents meaningful comparison with published literature, and introduces unknown variables into every experiment. Research-grade standard is ≥99% HPLC-verified purity — this ensures your dose is your dose.
What research combinations involve CJC-1295+DAC?
CJC-1295+DAC is most commonly researched in combination with GHRP compounds, particularly GHRP-2 and ipamorelin. The rationale for this research combination is mechanistic: CJC-1295+DAC activates the GHRH receptor while GHRPs activate the ghrelin receptor (GHSR-1a), two distinct signalling pathways that research literature suggests act synergistically in driving GH release amplitude. The GH Optimization Research Stack from Pure Grade Labs supplies both compounds for dual-pathway GH secretagogue investigation.
Does Pure Grade Labs supply Mod GRF 1-29 as well as CJC-1295+DAC?
Pure Grade Labs currently stocks CJC-1295+DAC 10mg specifically — the DAC-modified extended-release form. This is the form most commonly sought by researchers investigating sustained GHRH receptor stimulation, given its published pharmacokinetics and clinical data from the Alba et al. (2006) study. Check the full product catalogue for current stock.
What is the CAS number and molecular weight of CJC-1295+DAC?
CJC-1295+DAC has CAS number 863288-34-0 and a molecular weight of approximately 3,800 Da. These identifiers are printed on the Pure Grade Labs vial label and confirmed in the batch-specific COA. Confirming the CAS number against your COA and supplier listing is one of the simplest ways to verify you have received the correct compound.
Ready to Source Research-Grade CJC-1295+DAC?
HPLC ≥99% purity. Batch-specific COA. Lyophilised powder. UK stock. For laboratory research only — not for human consumption.
Summary
CJC-1295+DAC is a modified GHRH analogue with a Drug Affinity Complex modification that extends its half-life to approximately 19 days through covalent albumin binding — a pharmacokinetic profile that distinguishes it from all other GHRH research tools and makes it appropriate for sustained GHRH receptor stimulation studies, extended GH secretion kinetics research, and low-frequency dosing protocol designs. When searching to buy CJC peptide in the UK, researchers need to confirm two things with any supplier: that the DAC modification is present (not just Mod GRF 1-29), and that HPLC purity data ≥99% with a batch-specific COA is available. Low-purity CJC at 60–70% purity from unverified suppliers introduces a fundamental dose accuracy problem that undermines research data reliability.
Pure Grade Labs supplies CJC-1295+DAC 10mg verified to ≥99% HPLC purity with a batch-specific COA, from UK domestic stock, as lyophilised powder for laboratory research. CJC-1295 is not a controlled substance in the UK — it is legal to source and use for legitimate scientific research. For researchers investigating dual-pathway GH secretagogue mechanisms, GHRP-2 and the GH Optimization Research Stack are available alongside CJC-1295+DAC for complete GH axis research combination supply.
References
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. J Clin Endocrinol Metab. 2006;91(9):3560–3566. doi:10.1210/jc.2006-0291
- Jette L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052–3058. doi:10.1210/en.2004-1625
- Frohman LA, Jansson JO. Growth hormone-releasing hormone. Endocr Rev. 1986;7(3):223–253. doi:10.1210/edrv-7-3-223
- Müller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev. 1999;79(2):511–607. doi:10.1152/physrev.1999.79.2.511
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797. doi:10.1210/jc.2006-1702
- Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537–1545. doi:10.1210/endo-114-5-1537
Disclaimer: This article is for educational and informational purposes only and is directed at researchers and scientific professionals. Pure Grade Labs supplies CJC-1295+DAC strictly as a research chemical for laboratory use only. All products sold by Pure Grade Labs are not for human consumption, self-administration, or therapeutic use. Nothing in this article constitutes medical advice, prescribing guidance, or a recommendation for use in humans. This article does not represent a complete review of the scientific literature. Researchers should consult primary sources and apply their own scientific judgement to research design decisions. Pure Grade Labs is not responsible for outcomes arising from the use of research chemicals outside of approved laboratory research contexts.